Abstract
Serum levels of radioimmunoactive salmon calcitonin (sCT) were determined in 10 healthy volunteers after intranasal administration (IN) of 100-, 205-, and 450-IU of sCT with 0.5% sodium tauro-24,25-dihydrofusidate (STDHF), a 200-IU commercial IN formulation, and a 100-IU intramuscular (IM) formulation. Relative to the IM dose, the bioavailabilities of the IN formulations containing 0.5% STDHF were 3.9, 7.9, and 7.4%, respectively. The 200-IU commercial formulation resulted in serum levels above the limit of detection in only 5 of 10 patients, with an average bioavailability of 1.6%.
Similar content being viewed by others
REFERENCES
L. A. Austin and H. Heath. Calcitonin: physiology and pathophysiology. N. Engl. J. Med. 304:269–278 (1980).
D. J. Hosking. Treatment of severe hypercalcemia with calcitonin. Metab. Bone Dis. Relat. Res. 2:207–212 (1980).
J. DeRose, F. R. Singer, A. Avramides, A. Flores, R. Dzaiadiw, R. K. Baker, and S. Wallach. Response of Paget's disease to porcine and salmon calcitonins. Effects of long-term treatment. Am. J. Med. 56:858–866 (1974).
V. Fatourechi and H. Hunter. Salmon calcitonin in the treatment of postmenopausal osteoporosis. Ann. Intern. Med. 107:923–925 (1987).
H. W. Gruber, J. L. Ivey, D. J. Baylink, M. Matthews, W. B. Nelp, K. Sisom, and C. H. Chesnut. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303 (1984).
W. A. Lee and J. P. Longenecker. Intranasal delivery of proteins and peptides. Biopharm Manuf. 1:30–37 (1988).
C. McMartin, L. E. F. Hutchinson, R. Hyde, and G. E. Peters. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76:535–540 (1987).
J. Y. Reginster, D. Denis, A. Albert, and P. Franchimont. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. Bone Miner. 2:133–140 (1987).
J. Y. Reginster, A. Albert, and P. Franchimont. Salmon-calcitonin nasal spray in Paget's disease of bone: Preliminary results in five patients. Calcif. Tissue Int. 37:577–580 (1985).
K. Overgaard, B. J. Riis, C. Christiansen, J. Podenphant, and J. S. Johansen. Nasal calcitonin for treatment of established osteoporosis. Clin. Endocrinol. 30:435–442 (1989).
M. Hanson, G. Gazdick, J. Cahill, and M. Augustine. Intranasal delivery of the peptide, salmon calcitonin. In S. S. Davis, L. Illum, and E. Tomlinson (eds.), Delivery Systems for Peptide Drugs, Plenum Press, New York, 1986, pp. 233–241.
H. R. D'Agostino, C. A. Barnett, X. J. Zielinski, and G. S. Gordon. Intranasal salmon calcitonin treatment of Paget's disease of bone. Clin. Ortho. Relat. Res. 230:223–228 (1988).
J. F. Habner, F. R. Singer, L. J. Deftos, and J. T. Potts. Endocrinology 90:1102–1106 (1972).
P. A. Baldwin, C. K. Klingbeil, C. J. Grimm, and J. P. Longenecker. The effect of tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models. Pharm. Res. 7:547–552 (1990).
R. E. Stratford and V. H. L. Lee. Aminopeptidase activity in homogenates of various absorptive mucosae in the albino rabbit: Implications in peptide delivery. Int. J. Pharm. 30:73–82 (1986).
R. D. Ennis. Unpublished results.
W. A. Lee and P. A. Baldwin. Nasal membrances—structure and permeability. In H. Junginger (ed.), Drug Targeting and Delivery, Ellis Horwood, Chichester, 1993, pp. 219–232.
M. Azria and T. Cavanak. Calcitonin inhalation compositions. UK Pat. Appl. GB 2127689 A (1984).
M. S. Nolte, C. Taboga, E. Salamon, A. Moses, J. P. Longenecker, J. Flier, and J. H. Karam. Biological activity of nasally administered insulin in normal subjects. Horm. Metabol. Res. 7:547–552 (1990).
L. Hedin, M. Diczfalusy, B. Olsson, S. Rosberg, A. S. Pettersson, and K. Albertsson-Wikland. Nasal delivery of human growth hormone (hGH)—a new route of hormone administration in the treatment of GH-deficiency. Workshop on Current Trends in Growth Related Research, Haifa, Israel, Oct. 24–27 (1989).
G. Thamsborg, T. L. Storm, E. Brinch, R. Sykulski, N. Fogh-Andersen, S. N. Holmegaard, and O. H. Sorensen. The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium. Calcif. Tissue Int. 46:5–8 (1990).
T. Buclin, J. P. Randin, A. F. Jacquet, M. Azria, M. Attinger, F. Gomez, and P. Burckhardt. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif. Tissue Int. 41:252–258 (1987).
J. Y. Reginster and P. Franchimont. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin. Exp. Rheum. 3:155–157 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, W.A., Ennis, R.D., Longenecker, J.P. et al. The Bioavailability of Intranasal Salmon Calcitonin in Healthy Volunteers with and Without a Permeation Enhancer. Pharm Res 11, 747–750 (1994). https://doi.org/10.1023/A:1018992716621
Issue Date:
DOI: https://doi.org/10.1023/A:1018992716621